Inhibition of lentiviral nuclear import pathways by Mx2
- Institution
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA
- Principal investigator
- Melissa E Kane
- Funding
- $395K
- Duration
- 2021–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY/ABSTRACT Lentiviruses such as HIV-1 are uniquely efficient in their ability to infect non-dividing cells through the hijacking of cellular nucleocytoplasmic trafficking pathways. Nuclear import of primate lentiviruses is inhibited by the interferon inducible GTPase Mx2, which localizes to the nuclear pore complex. However, the process by which HIV-1 utilizes cellular nucleocytoplasmic trafficking and how nuclear entry is inhibited by Mx2 remain poorly defined. Furthermore, the relationship between Mx2 and other cellular proteins that affect the pre-integration stages of HIV-1 infection is not understood. We have previously demonstrated that the antiviral activity of Mx2 is affected by cellular nucleocytoplasmic trafficking pathways in a cell-type, cell-cycle, and HIV-1 capsid- dependent manner. We further determined that Mx2 inhibits nucleocytoplasmic trafficking of non-viral cargo in a cell-type dependent manner, indicating that it may have broader functions in antiviral interferon responses. Here, we aim to determine how Mx2 is localized to the nuclear pore complex, the nuclear import pathways that are inhibited by Mx2, how Mx2 is affected be heterogeneity in nucleocytoplasmic trafficking, and how Mx2 affects the interaction of HIV-1 with other antiviral proteins.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Pittsburgh at PittsburghNot yet scored
Genetic basis for interferon-gamma-independent antiviral antibody production
Melissa E Kane · $74K · 2024–2026
- NIH · University of Pittsburgh at PittsburghNot yet scored
Genetic basis for TLR7-independent antiretroviral antibody responses
Melissa E Kane · $199K · 2024–2026
- NIH · University of Pittsburgh at Pittsburgh64
Core E: Omics Core
Sid E O'Bryant · $3.2M · 2020–2026